Fairhaven Pharmaceuticals

Fairhaven Pharmaceuticals in its acquisition by Liminal BioSciences

Client

Fairhaven Pharmaceuticals

Value

-

Service

Emerging and High Growth Companies

Date Closed

July 2020

Lead Office

Toronto


 

On July 17, 2020, Fairhaven Pharmaceuticals announced that it has been acquired by Liminal BioSciences. The acquisition includes Fairhaven’s preclinical research program of small molecule antagonists. Investigational therapies developed in the R&D program target a key chemoattractant and activator of eosinophils, which play a key role in inflammation-driven diseases.The acquisition continues Liminal’s strategic expansion to create a diverse portfolio of early stage R&D programs that complement its existing research.

Fairhaven Pharmaceuticals specializes in the development of small molecule, oral therapeutics for severe inflammatory conditions.

Liminal BioSciences is a clinical stage biopharmaceutical company specializing in discovering, developing and commercializing treatments for patients suffering from diseases related to fibrosis.  

Osler, Hoskin & Harcourt LLP advised Fairhaven with a team consisting of David Jamieson, Kosta Starostin (Corporate), Martha Martindale (Financial Services), Colena Der (Taxation) and Amelia Miao (Securities).  


Team
David Jamieson
Key Contact

David Jamieson

Partner, Emerging and High Growth Companies

Konstantin (Kosta) Starostin

Konstantin (Kosta) Starostin

Associate, Emerging and High Growth Companies

Martha Martindale

Martha Martindale

Partner, Financial Services

Colena Der

Colena Der

Partner, Taxation

Amelia  Miao

Amelia Miao

Associate, Corporate